newsfilter
← Latest News
PR Newswire·

Phio Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Initiated dosing of subjects and enrollment ongoing in the first-in-human clinical study of PH-762 for the treatment of advanced melanoma; expect to announce top-line data from the first group of subjects in Q1 2023 Expects to initiate a clinical trial